MicroRNA-497 Inhibits Cardiac Hypertrophy by Targeting Sirt4

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Dec 20

PMID 27992564

Citations 21

Authors

Yimin Xiao

Xiaofei Zhang

Shihao Fan

Guanghao Cui

Zhenya Shen

Affiliations

Soon will be listed here.

Abstract

Cardiac hypertrophy is an adaptive enlargement of the myocardium in response to overload pressure of heart. From abundant studies, a conclusion is drawn that many microRNAs (miRNAs) are associated with cardiac hypertrophy and heart failure. To investigate the role of microRNA-497 (miR-497) in myocardial hypertrophy, two models were established in this study from cell level to integral level. Cardiac hypertrophy was induced by using angiotensin Ⅱ (Ang Ⅱ) in vitro and was created by transverse abdominal aortic constriction (TAC) in vivo. There was a significant decrease expression of miR-497 in cardiac hypertrophy models. Moreover, overexpression of miR-497 inhibited myocardial hypertrophy both in vitro and in vivo without heart function variation. In addition, luciferase reporter assays demonstrated that Sirt4 was a direct target gene of miR-497. Taking together, our study indicates that miR-497 modulates cardiac hypertrophy by targeting Sirt4 and may serve as a potential therapeutic substance in the course.

Citing Articles

CoCl -triggered pseudohypoxic stress induces proteasomal degradation of SIRT4 via polyubiquitination of lysines K78 and K299.

Hampel N, Georgy J, Mehrabipour M, Lang A, Lehmkuhl I, Scheller J FEBS Open Bio. 2023; 13(12):2187-2199.

PMID: 37803520 PMC: 10699113. DOI: 10.1002/2211-5463.13715.

SIRT4 in ageing.

He L, Liu Q, Cheng J, Cao M, Zhang S, Wan X Biogerontology. 2023; 24(3):347-362.

PMID: 37067687 DOI: 10.1007/s10522-023-10022-5.

The dysregulation of plasma miR-497/FGF23 axis, and its association with clinical characteristics and major adverse cardiovascular event in female premature acute coronary syndrome patients.

Jiang Y, Cai W, Cai G, Wang D, Wu Q Ir J Med Sci. 2023; 192(5):2105-2115.

PMID: 36645571 DOI: 10.1007/s11845-022-03256-8.

MiRNA-29b and miRNA-497 Modulate the Expression of Carboxypeptidase X Member 2, a Candidate Gene Associated with Left Ventricular Hypertrophy.

Subrova J, Bohme K, Gillespie A, Orphal M, Plum C, Kreutz R Int J Mol Sci. 2022; 23(4).

PMID: 35216380 PMC: 8880112. DOI: 10.3390/ijms23042263.

Mitochondrial nucleoid in cardiac homeostasis: bidirectional signaling of mitochondria and nucleus in cardiac diseases.

Feng Y, Huang W, Paul C, Liu X, Sadayappan S, Wang Y Basic Res Cardiol. 2021; 116(1):49.

PMID: 34392401 PMC: 8364536. DOI: 10.1007/s00395-021-00889-1.

References

Li X, Zeng Z, Li Q, Xu Q, Xie J, Hao H . Inhibition of microRNA-497 ameliorates anoxia/reoxygenation injury in cardiomyocytes by suppressing cell apoptosis and enhancing autophagy. Oncotarget. 2015; 6(22):18829-44. PMC: 4643066. DOI: 10.18632/oncotarget.4774. View

Raut S, Singh G, Rastogi B, Nahar Saikia U, Mittal A, Dogra N . miR-30c and miR-181a synergistically modulate p53-p21 pathway in diabetes induced cardiac hypertrophy. Mol Cell Biochem. 2016; 417(1-2):191-203. DOI: 10.1007/s11010-016-2729-7. View

Tijsen A, van der Made I, van den Hoogenhof M, Wijnen W, van Deel E, de Groot N . The microRNA-15 family inhibits the TGFβ-pathway in the heart. Cardiovasc Res. 2014; 104(1):61-71. DOI: 10.1093/cvr/cvu184. View

Luo Y, Tang X, An X, Xie X, Chen X, Zhao X . SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. Eur Heart J. 2016; 38(18):1389-1398. DOI: 10.1093/eurheartj/ehw138. View

Ge L, Zheng B, Li M, Niu L, Li Z . MicroRNA-497 suppresses osteosarcoma tumor growth and . Oncol Lett. 2016; 11(3):2207-2212. PMC: 4774554. DOI: 10.3892/ol.2016.4162. View

Kamo T, Akazawa H, Komuro I . Cardiac nonmyocytes in the hub of cardiac hypertrophy. Circ Res. 2015; 117(1):89-98. DOI: 10.1161/CIRCRESAHA.117.305349. View

Potter G, Burlingame S, Cragoe E, Sellin J . Electrogenic sodium transport in the developing rabbit cecum. J Pediatr Gastroenterol Nutr. 1989; 8(4):516-21. DOI: 10.1097/00005176-198905000-00016. View

Lv D, Liu J, Zhao C, Sun Q, Zhou Q, Xu J . Targeting microRNAs in Pathological Hypertrophy and Cardiac Failure. Mini Rev Med Chem. 2015; 15(6):475-8. DOI: 10.2174/1389557515666150324124751. View

Liu J, Zhou Y, Shi Z, Hu Y, Meng T, Zhang X . microRNA-497 Modulates Breast Cancer Cell Proliferation, Invasion, and Survival by Targeting SMAD7. DNA Cell Biol. 2016; 35(9):521-9. DOI: 10.1089/dna.2016.3282. View

10.

Vegter E, van der Meer P, De Windt L, Pinto Y, Voors A . MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. 2016; 18(5):457-68. DOI: 10.1002/ejhf.495. View

11.

Mukku R, Fonarow G, Watson K, Ajijola O, Depasquale E, Nsair A . Heart Failure Therapies for End-Stage Chemotherapy-Induced Cardiomyopathy. J Card Fail. 2016; 22(6):439-48. DOI: 10.1016/j.cardfail.2016.04.009. View

12.

Shimizu I, Minamino T . Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 2016; 97:245-62. DOI: 10.1016/j.yjmcc.2016.06.001. View

13.

Yang L, Li Y, Wang X, Mu X, Qin D, Huang W . Overexpression of miR-223 Tips the Balance of Pro- and Anti-hypertrophic Signaling Cascades toward Physiologic Cardiac Hypertrophy. J Biol Chem. 2016; 291(30):15700-13. PMC: 4957053. DOI: 10.1074/jbc.M116.715805. View

14.

Verdin E, Hirschey M, Finley L, Haigis M . Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci. 2010; 35(12):669-75. PMC: 2992946. DOI: 10.1016/j.tibs.2010.07.003. View

15.

Communal C, Singh K, Pimentel D, Colucci W . Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation. 1998; 98(13):1329-34. DOI: 10.1161/01.cir.98.13.1329. View

16.

Ono K . microRNAs and Cardiovascular Remodeling. Adv Exp Med Biol. 2015; 888:197-213. DOI: 10.1007/978-3-319-22671-2_10. View

17.

Zhu Y, Yan Y, Principe D, Zou X, Vassilopoulos A, Gius D . SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis. Cancer Metab. 2014; 2:15. PMC: 4203689. DOI: 10.1186/2049-3002-2-15. View

18.

Sun X, Zhang C . MicroRNA-96 promotes myocardial hypertrophy by targeting mTOR. Int J Clin Exp Pathol. 2016; 8(11):14500-6. PMC: 4713555. View

19.

Greco C, Condorelli G . Epigenetic modifications and noncoding RNAs in cardiac hypertrophy and failure. Nat Rev Cardiol. 2015; 12(8):488-97. DOI: 10.1038/nrcardio.2015.71. View

20.

Tarantino G, Finelli C, Scopacasa F, Pasanisi F, Contaldo F, Capone D . Circulating levels of sirtuin 4, a potential marker of oxidative metabolism, related to coronary artery disease in obese patients suffering from NAFLD, with normal or slightly increased liver enzymes. Oxid Med Cell Longev. 2014; 2014:920676. PMC: 4086623. DOI: 10.1155/2014/920676. View